The plant herb Artemisia annua (Qing Hao) has been used in China for over 400years to treat malaria disease, which has a mostly higher prevalence in the tropics where it is more endemic. Also, it has been used to kill parasitic worms, as anti-microbial agents, and has found non-medicinal uses in the United States and Europe. The active anti-malarial compound in A. annua called Artemisinin was isolated in the 1970s.
INTRODUCTION
Artemisia annua is a short day-plant possessing a shoot and root system and could attain a height of around 2metres (Ferreira et al, 1995a; McVaugh, 1984) . Historically, Artemisia plants have been traditionally grown in China, and have been found to be a component of the plant flora in Asia-with notable presence in countries like China, Vietnam and India (Gray 1959; CDC 2012) . The chromosome number of A. annua is derived from the genetic equation 2n = 36.
In recent years, the plant has been found to now grow wild in America and Europe, and Artemisia annua has also been introduced for cultivation in high altitude African Nations in East and Central Africa (Bui et al, 2 0 1 1 ) , in
Justification and objectives of this review article:
Malaria is a disease resulting from an infection by a Protozoan Plasmodium parasite, and it has been found that one of the causes of cancer is through infection by a virus leading to what is called "cervical cancer". Invariably, both malaria and cervical cancer could be treated, except that malaria can not be prevented through usage of a vaccine while a vaccine for cervical cancer exists. Several species of Plasmodium exist in both humans and lower animals of which include rodents, reptiles, monkeys, chimpanzee and other animals. The Plasmodium species infecting Man include P. falciparum, P. vivax, P. ovale, and P. malariae; and in recent times, some other species and sub-species have been identified (WHO, 2012) , Though the tide of the burden of malaria is been stemmed down in some countries, its incidence may be rising in some other countries while in some countries where it has been previously eradicated, malaria appear re-emerging. Then, the issue of resistance to antimalaria drugs have propelled the need to step up efforts to maintain the presence of potent antimalaria drugs in our drug portfolio. (WHO, 2010; WHO, 2011; Van-Tyne, 2011) .
Globally, between 300-500million cases of malaria infection are reported annually, while between 1 to 1.2million deaths are recorded yearly from these cases. One fifth of the world's population is reportedly at risk of being infected (Hollyman, 2015) . Between 3.2 and 3.3 billion people live in areas at risk of malaria transmission in 100countries and territories (CDC, 2012; Hollyman, 2015) .
In Nigeria the most populous black nation on earth, N132 billion (Naira) is lost to the disease as cost of treatment and loss of man hours, malaria account for 63% of all visits to public health facilities, 29% of childhood death, 25% of infant mortality and 11% of maternal mortality (LSM, 2016) .
Malaria is a problem in the 1 st and 2 nd pregnancies and may cause parturition of babies with low birth weight and other associated problems. About 9 to 10 clinical cases of malaria occur in Africa. Children below 5years, pregnant women, and travelers with non-immune status from non-endemic countries who travel to endemic countries are among those usually at risk of infection (CDC, 2015) . As part of the global war against malaria, an attempt to check the spread of malaria disease by the year 2015 during which man would have begun to attempt to significantly reduce the number of new cases-is one of the millennium development goals which were set in year 2000.
Artemisisnin is of biological importance because of its outstanding antimalarial activity (CDC 2012) and its has been reported through publications in reputable journals that it has anti-tumour potentials (Nam et al, 2007; 2004, Crespo-Oritz and Wei, 2012) .
The number of cancer deaths is 171.2per 100,000 men and women per year (based on 2008-201 deaths in the United States (National Cancer Institute, 2015) . There are several types of cancer named according to the region or organ of the body affected. Unlike malaria which manifests in fewer forms in terms of disease state (uncomplicated mild and severe malaria types, with specific types such as cerebral malaria common among children), several forms of cancer exists which are associated with specific concentrated manifestations in various parts of the body. Typical examples include:
Colon cancer, Pancrearic adenocarcinoma, Brain malignancy (Brain cancer), Prostate cancer, Cervical cancer, Ovarian cancer, Leukaemia, Breast cancer, Skin cancer, Lung cancer, CNS cancer, among others (National Cancer Institute, 2015) . Among these several cancer types, the globally leading causes of death by cancer appear to be lung, liver, stomach, colorectal types of cancer (WHO, 2016; De Martel et al, 2012; World Cancer Report, 2014) . Among women, it was breast, colorectal lung and cervix cancer as the leaders in terms of death toll, and it was lung prostate and colorectal among men.
The use of ACTs derived from Artemisia in form of combination therapies to successfully treat individual malaria cases, and foraging into exploits of attempts to use it for treatment of cancer on one hand, and its possible consequent impact on large scale populations can provide information that directly affect the health of millions of people globally each year, with its attendant public health significance, This goes not only for Artemsinin, but also for related analogues of Artemisinin which have come in handy for treatment of malaria and attempts for treatment of cancer.
The antimalarial properties of Artemisinin and its mode of action, success story and impact of Artemisinin on war against malaria, the shortcomings in the chemical structure of Artemisinin with regards to effectiveness as an anti-malarial, attempts at improving its shortcomings and introduction non-synthetic derivative analogues, introduction of ACTs and benefits from ACTs' based chemotherapy of malaria, active compound in A. annua for cancer chemotherapy, and A. annua Genetic Resources and its benefits for malaria and cancer treatment have been presented in this article, all in one synchronized piece.
History of use of Artemisia for malaria treatment
For over four centuries, A. annua has been associated with the treatment of malaria, a disease which is known to be accompanied by several symptoms of which include fever. Considering the fact that documentation of evidence that A. annua was used to treat fever as far back as 340AD, around when the Handbook of Prescriptions for Emerging Treatment was published, it may not be unlikely therefore, that some of the treated cases of fever may have been possibly due to Plasmodium malaria infection. Moreso, recalling that malaria was first described in 400BC by Hippocrates. However, a publication dated to 1596 contained a description of the use of A. annua to treat chills and fever caused by malaria in China (McVaugh, 1984; Efferth 2007) . At a stage in history, Artemisia annua was used to treat worm infections (Wright, 2002; Graziose et al, 2010) . Ukoh and Ozurumba (2016) from their study, observed that intestinal parasitic infections (IPIs) (caused by worms) such as Taenia, Strongyloides, Hookworm, Schistosoma-to a higher extent in terms of prevalence, and to a lesser extent-Trichuris, Cryptosporidium and Dicrocoelium dendriticum were the ones found to be most prevalent in a certain population in North eastern Nigeria; with the first group requiring more public health attention than the second group at the period of the study (Ukoh and Ozurumba, 2016) .
Currently, the active compound of A. annua has been used to treat malaria in well over hundreds of thousands of people in China and Vietnam and has now extended to the global level in the area of its usage as an antimalarial-be it in form of monotherapies or in form of combined therapies called artemisinin combined therapy-ACT (Klayman 1993; WHO, 2012) .
A plant of Artemisia annua is now known to yield 0.3-0.5% Artemisinin (Woerdenbag et al, 1984; Delabays et al, 1993; WHO, 2006) . High level semi-synthetic production the potent antimalarial Artemisinin was invented and described by Paddon et al (2013) , providing a biosynthetic route to production of artemisinic acid using a dehydrogenase and a 2 nd cytochrome that facilitated efficient biosynthesis.
Chemical Structure and properties of Artemisinin (Qinghaosu)
Artemisinin is an aromatic compound with a molecular mass of 282,332g/mol and possess a 3D structure (PUBCHEM, 2016) . It was originally introduced for the treatment of resistant Plasmodium falciparum malaria and has been reportedly used to treat vivax malaria. Artemisinin is a naturally occurring endoperoxide sesquiterpene lactone, forms colourless orthorhombic crystals that are soluble in alcohol and in ethyl acetate (Meshnik et al, 1996; Crespo et al, 2007) . It is a quadricycle, possessing a basic structure of 4 rings. One of these four rings has a peroxide linkage as part of the ring. Also, it is an endoperoxidase, containing a peroxide linkage of two oxygen (O-O) between 2 points on one of the rings. A sensitive endoperoxide bridge is shielded by a Ring system (WHO, 2006) .
Antimalarial properties of Artemisinin and mode of action
Artmisinin exerts its properties as an anti-malarial compound through a pharmacophoric peroxide bond in a unique 1,2,4-trioxane heterocycle. The peroxide bridge or bond in Artemisinin is critical for its chemotherapeutic antimalarial activity (Crepo et al, 2007) . A secondary ozonide contains the endoperoxide bridge that is critical and vital for the antimalarial action of Artemisinin. This endoperoxide bridge is unstable and stability was improved upon by the emergence of some developed synthetic and semi-synthetic analogues to Artemisinin.
Several years back, it was hypothesized that Artemisinin reacts with a chemical compound that is found at high concentrations on the surface of Plasmodium parasite. This chemical compound has high concentrations of Iron. The reaction between the chemical compound and Artemisinin then lead to a cascade of other reactions that eventually lead to killing of the parasite.
Following this malaria parasite Iron and Artemisinin reaction, some other chemical reactions occur which spawn charged atoms called "free-radicals". These free radicals then attack the parasite cell membrane through a lytic process that dismembers the parasite's cell membrane and lead to the killing of this unicellular protozoan Plasmodium parasite (Harrill, 2001) .
This hypothesis may not be an unlikely event, as certain insights by Ozurumba in his previous researches, some of which have partly published. One of them revealed that a compound in the form of Iron (III) Haem accumulates in the Plasmodium parasite in an event involving Haemoglobin digestion in the parasite (Ozurumba, 2012) .
Shortcomings in Chemical structure with regards to effectiveness as an anti-malarial
Though Artemisinin has shown lots of promise as an effective anti-malarial, being successfully engaged against uncomplicated malaria, clears all gametocyte stages of the parasite from the mammalian system, worked in cerebral malaria cases in children-helping to revive the children and recover; certain features in the chemical structure of Artemisinin have been found to be some of its few areas of shortcomings in its efficacy as an anti-malarial.
Artemsinin is poorly soluble in water, while the endoperoxide bridge appears to be unstable as this sensitive peroxide bridge is shielded by a Ring System (WHO/TDR, 2004 , WHO, 2006 . Also, the bio-availability of Artemisinin based antimalarials is a shortcoming in Artemisinin malaria therapy.
Artemisinin has a short half-life which also manifests in its other form that is used in Artemisinin combination therapy, as one of the factors that tend to cause some of the few related drug resistance problems by Plasmodium, recorded for Artemisinin based therapies, be it mono or combined therapies. Its short half-life and bio-availability defects are problems related to its bio-pharmaceutical profile.
Attempts at improving shortcomings and non-synthetic derivative analogues
Though some non-synthetic derivatives of Artemisinin have been developed, and are produced by pharmaceutical companies in form of Artesunate, Artemether and few others, attempts are being made to improve on the shortcomings in Artemisinin by developing semi-synthetic and synthetic analogues of Artemisinin (WHO/TDR, 2004) geared towards solving or reducing the defects and challenges related to availability of the anti-malarial, water solubility, stability and cost. Many of these efforts have received support and funding from the WHO and MMV. One of such synthetic analogues include: OZ227.
The synthetic analogue OZ227 that was developed by a scientist based in the United States-at the period of its initial development, this compound had an improved solubility in water and was more stable than Artemisinin (Crespo et al, 2007) . However, OZ227 was not entirely devoid of defects. For instance, though it was more water soluble than Artemisinin, it was still regarded as having poor solubility in water, based on standard yardsticks for determining water solubility (WHO/TDR, 2004) . In addition, oral administration of 0Z227 showed that it was not very reactive via this route for treatment.
Success stories and impact of Artemisinin on war against malaria
As at 2010, scientists believed that no other natural non-synthetic chemical compound with its unique endo-peroxide bridge is known. This scenario would remain the same unless another natural compound with such anti-malarial property is discovered. However, each anti-malarial of completely different basic chemical structure tend to have different inherent antimalarial mode of action and properties.
Traditionally in China, Artemisia (Qing Hao), has been used for reducing fevers, inflammation, headache and treat malaria. Artemisia has been reportedly used on over 1million patients in China and Vietnam to treat cases of malaria (Graziose et al, 2010) .
Apart from oral and intravenous routes of administration of Artemisinin based drugs from which successes have been recorded, anti-malarial suppositories derived from A. annua have been developed, which are injected rectally. This has been engaged in remote areas in endemic countries as emergency lines of initial treatment before the patient reaches the hospital for follow-up treatment. Artemisinin has been used to successfully treat falciparum and vivax malaria. A. annua has been widely used in the tropics for both prevention and treatment of malaria. Its active compound Artemisinin has been found to treat malaria and relatively free of side effects. The use of Artemisinin by itself is a monotherapy. Artemisinin was introduced for the treatment of resistant Plasmodium malaria. Artemisinin based monotherapy involving use of its non-synthetic derivatives such as Artemether, Artemotil, Artesunate, Artenmal and sodium Artesunate have recorded various levels of efficacy against falciparum malaria and were found to be more effective than Quinine based antimalarials such as Chloroquine and Mefloquine drug lines that were at a stage, the first line of treatment which were beginning to fail during treatment-showing drug resistance, had adverse reactions on patients such as extreme bitter taste and intense itching among others, which the introduced Artemisinin based drugs did not possess.
Quinine-derived antimalaria drugs such as chloroquine were used in the 1960s during the period of campaign to eradicate malaria worldwide. There had been initial success before the malaria parasites were found to be developing resistance to these quinine-derived medicines, which negatively affected the efficacy of the drug and interrupted the initial success.
This placed a burden and strain on the need to develop new drug application strategies to effectively treat the disease and fight back the clever evasive action mounted by the parasite against drug-potency. Thus, ACTs which were originally developed by the Chinese in form of Artemisinin based monotherapy before it was upgraded into combined therapeutic forms in the ACTs-was recommended by WHO as first line of treatment for malaria treatment in several affected tropical countries.
The demand for ACTs at a period between 2010 and 2011 was close to 100million, while this figure has been estimated to reach around 190million or more by the year 2012 (then, meeting the demand at the level it could be in 2012 seem to be the new challenge as earlier indicated) (WHO, 2011; Morris et al, 2014) .
Evidences of resistance by Plasmodium to Artemisinin based monotherapy (Artemisinin and its derivatives) were observed in some endemic countries in Southeast Asia such as Cambodia (Kariko, 2015) among other countriesencouraged the need for an innovative type of treatment with Artemisinin in the form a combination therapy. Thus, a treatment paradigm shift from Artemisinin based monotherapy to Artemisinin based combination therapy (ACT) was birthed. The WHO at this stage started discouraging Artemisinin based monotherapy in favour of ACTs. ACTs have been found to be highly effective against malaria parasites that have exhibited resistance to antimalarials (CDC, 2010) . Thus, ACTs appear to be one of the few options available for treating malaria.
Several combinations in the ACTs have been developed and are in use, of which includes: ArtemetherLumefantrine, Artesunate-Mefloquine, Dihydroartemisinin-piperaquine, Artesunate-Amodiaquine and ArtemisunatePyrimethamine-Sulfadoxine.
Several other ACTs are being worked out for development. These includes:
Artesunate-Chloroproguanil-Dapsone, among others. However, Amodiaquine and Pyrimethamine-Sulphadoxine are said to be longer acting antimalarials of longer half lives. This property may make them suitable for combinations with ACTs, which is a combination of both.
Some benefits from ACTs' based chemotherapy of malaria:
These benefits includes reduced risks from its usage such as adverse effects and reduced chances of progression of infection from uncomplicated to severe form of the disease and mortality, and its relieving and curing more persons affected by the disease more than other antimalarials. Thus, ACTs have been found to limit the chances of emergence of drug resistance by malaria parasite.
Finally, areas with high intensity (high transmission rates of malaria), a combination of two longer-acting antimalarials has been suggested because in such areas, the general success rate with ACTs may be challenged by factors such as partial immunity and resolution of symptoms with incomplete dosage treatment. This is unlike the observed high success rate with ACT usage in areas of low intensity of malaria.
Some of the major reasons attributed for the emergence of anti-malarial drug resistance include: . Non-compliance with drug dosage regimen that are ineffective. Slow clearance of the drug from the human system during usage. Use of anti-malarials whose quality may have nose-dived possibly due to storage conditions. Widespread haphazard usage of anti-malarials, among other reasons.
Overt time, the levels of resistance by the parasite to treatment courses with Artemisinin and its derivativesbased monotherapy has increased.
History of attempts or engagement of A. annua based compounds against cancer
In 1972, the active compound involved in treating malaria and its accompanying fever was characterized and led to the formal documentation and approval of A. annua to treat malaria-especially in its processed forms that incorporate its active compound called Artemisinin. Drugs such as Artemotil and Artemetherin (in monotherapies) among others have come to light in treating malaria, before they got incorporated into other therapeutic forms called Artemisinin combination therapies ACTs, a combined therapeutic form. A. annua against malaria has been a great discovery as it had immense impacts on malaria control via therapy. Also, A. annua found usage to treat parasitic infections involving worms, some microbes and fungal infections (Harrill, 2001) . By and large, it may have given clues of need to attempt its usage against a disease that has also ravaged humans like malaria, which is cancer.
Cancer may be induced by either parasitic (pathogenic) or non-parasitic agents. Then, there is cancer having parasitic and non-parasitic inducers of the disease condition.
In the late 1990s, a group of researchers in Cancer Biology led by a distinguished Professor Lai in the United States of America, took a closer look at Artemisinin and its usage against malaria, examined the mechanism of action of the active compound Artemisinin against the Protozoa malaria parasite Plasmodium. The lead scientist's insight into the event led to his hypothesizing that the process through which Artemisinin reacts with a chemical compound Iron, noticed to accumulate at high concentrations in the Plasmodium parasite, leading to the eventual killing of the parasite after a series of reactions, might possibly either have a killing effect or impact on cancer cells or work as a drug against cancer disease (as a drug whose components may still be on investigation).
Eventual attempts by the lead scientist in the team, surprisingly recorded apoptoses of nearly all breast cancer cells while the normal breast cancer cells appeared unaffected or minimally affected. The success of his team seem to have encouraged them to attempt using Artemisia against another type of cancer called Leukaemia. The team got some positive results.
Similar successes were recorded in the studies of the following scientists:
. Singh et al (2004) in which dihydroartemisinin DHA treatment was found to significantly decrease cell counts while increasing the proportion of apoptosis in cancer cells compared to controls; . Nam et al (2002) observed and remarked that deoxyartemisinin trimer had greater anti-tumour effect on tumour cell lines than other commonly used chemotherapeutic drugs such as 5-FU, Cisplatin and Paclitaxel; . Mu et al (2008) finding that DHA induce apoptosis of lung cancer cell line PC-14 cells with calcium and P38 playing roles in apoptosis signaling pathways; . Zhou et al (2008) identifying induction of apoptosis in human leukemia cells HL60 by DHA; . Singh et al (2005) which studied and noted the synergistic anti-tumour action of Artemisinin and sodium butyrate on cancer cells with artemisinin found to selectively kill cancer cells in vitro while sparing normal cells; . Li and Hickman (2011) remarked that several studies have demonstrated that ART s and their derivatives possess anti-angiogenic activity and inhibition of cancer progression.
Ever since, the earlier mentioned team of scientists (led by Lai) appeared to have stepped up gear with experiments both in-vivo in animal models like Dog and in-vitro in diverse forms of cancer. In recent times, attempts have been made to treat skin cancer in humans using Artemisinin based drugs in form of oral and topical (rubbed on the skin) medications. Instances have been recorded and reported in some south-east Asian countries.
Worthy of note is the use of some new herb plants which have been screened and discovered to show anticancer properties to battle cancer; thus complimenting and joining the race in the attempts and engagement of well synthesized plant products to combat and treat of Cancer. Some of these new plant derived anti cancer agents in clinical use include Vinca alkaloids, Vinblastine VLB, and Vincristine VCR isolated from Catharanthusroseaus G. Don (Apocynaceae), extracts from Podophyllaceae family and Paclitaxel derived from leaves of Taxus species and extracts from Archeranthes aspera plant (Prakash et al, 2013) .
Possibly with time, some combinations of the active anti-cancer compounds in these herb plants and plants, could be found to possess "growth advancement inhibition capacities" against raging cancer, in the multi-faceted attempts by man against the threat posed by "these strange and deranged cells that grow for the sake of growth but with no clearly constituted means of modulating the growths".
Active compound in A. annua for cancer chemotherapy
In studies and investigations examining compounds derived from the A. annua plant for treating cancer, some monotherapeutic and combined therapeutic forms of the drug have been examined and screened for levels of potency and toxicity on the animal models, before they were attempted on humans.
Some of these drugs have included: Dihydroartemisinin, Coartem, and Dihydroartemisinin in combination with Holotransferrin to confer some properties that make Dihydroartemisinin effective, among other forms (PUBCHEM, 2016) .
Tumour cells have been found to have an enhanced vulnerability to ROS damage as they exhibit lower expression of antioxidant enzymes such as superoxide dismutase, catalase and gluthatione peroxide compared to that of normal cells; while artemisinin has been linked to artemisinin cytotoxicity to factors of which include enhanced level of oxidative stress (Gorrini et al, 2013) . It is worth noting that the preloading of cancer cells with iron or iron saturated holotransferrin (diferric transferring) has been found to cause artemisinin cytotoxicity (Gorrini et al, 2013) increasing the activity of artemisinin by values close to 100fold in some cell lines (Crespo-Orittz and Wei, 2012) . The derivatives of artemisinin such artesunate, arteether and artemether have been found to exhibit anti-tumour activity against melanoma, breast, ovarian, prostrate, CNS and renal cancer cell lines (Nam et al, 2007) .
By and large, the active compound in these therapeutic drug forms attempted against cancer had been Artemisinin which in Chinese is called Qinghaosu. In some forms of the drug, Artemisinin has been aided to be effective by compounds that bind on to cell-surface receptors to facilitate certain processes that enhance drug action potency of Artemisinin. For instance, cancer cells exhibit an increase in transferring receptors which have been found to be responsible for the iron uptake and regulation of intracellular concentrations (Gorrini et al, 2013) .
Artemisinin and its derivatives are among compounds whose anti-tumour activities have been discovered through discovery efforts that focus on screening drugs that are engaged in other diseases and other plant products.
The 1 st account of anti-cancer activity of artemisinin and its derivatives was presented in 1993 while Lai and Singh (1995) made their landmark contribution through their publication in which they presented the selective killing of MOLT-4 lymphoblastoid leukemic cells by artemisinin.
Moving from the petri-dishes, test tubes and laminar flow hood in-vitro chamber to the real life cases on the field and in the clinic, it was reported in the Dec 15 th 2004 that artesunate and artemisinin were successfully used to treat grafted human tumors in laboratory animals; while the German scientist Efferth and his team demonstrated the antitumour activity of artemisinin and some of its derivatives against leukemia and colon cancer and what the group called 'modest anti-cancer activity against melanoma, ovarian, breast, prostrate and renal cancer. In a follow-up by the same Efferth's research team, their attempt to treat two melanoma patients with ART artesunate after chemotherapy had failed, resulted in one of the patients going on to live for 24months and the 2 nd patient for 47months as at 2007 which went beyond the median survival of 2-5months using other chemotherapy (Chang, 2012) .
A report by WRAIR Silver Spring, USA, published online in 2013 by "In Tech Open", presented the use of artemisinin and its derivatives as angiogenesis inhibitors to treat cancer.
A. annua Genetic Resources: genetic map and benefits for malaria and cancer treatment
In the light of the foregoing, it seems imperative to have a genetic resource for the plant herb A. annua, considering its varied uses in natural medicine and modern synthesized medicinal drugs, alongside its numerous non-medicinal uses. In developing a genetic resource for A. annua, it has incorporated intensive study and observations to complete and produce the first genetic map for the plant.
Some of the prominent research teams who have made valuable contributions to the genetic resources of A. annua include those at the University of York, Mediplant in Switzerland, CPOBA -UNICAMP in Brazil and CIMAP Luknow which has a vital presence in India.
The first genetic map of A annua provided information on the loci for Artemisinin, the active compound in A. annua engaged against malaria disease and being investigated for its potency and possible engagement against cancer (Nordquist; 2010; Graham et al, 2010) .
CONCLUSION
The journey on the war against malaria, using the antimalarial Artemisinin derived directly either from the herb plant Artemisia annua or from synthetically produced forms of this drug, has been interesting and challenging. This took the form of the emerged ACTs, developed by scientists to overcome the drug resistance challenge to Artemisinin and its analogues, posed by Plasmodium parasites. Several analogues of Artemisinin have since emerged, all contributing to the same global fight back against malaria. The exploitation of some of the attributes in mode of action of Artemisinin to clear malaria parasites by oncologists and drug development experts to target the killing of cancer cells has been tough and challenging with some levels of successes but yet to get to the level of synchronizing the various results into the 1 st real potent Artemisia annua or Artemisinin compound involving drug against cancer. Like attempts with use scientifically synthesized Artemisia annua derived chemical compounds against cancer, there are a myriad of other herb plants being investigated through use of some observed active compounds in these herb plants, for potency against cancer, with some of them also showing some levels of successes. By and large, the impactful public health implications of the success of ACTs incorporating Artmisinin and its analogues in contributing to the reduction of the burden of malaria on humans, appears obvious; with that of its impact on cancer burden still speculative at present.
ACKNOWLEDGEMENTS:
Ozurumba appreciates Prof Walter G. Land-a Transplantation, Immunology& Oncology expert; & Prof Claude P. Muller (Molecular Immunologist-Luxembourg) for inspiration and trainings. Also, he expresses gratitude to School of Public Health, College of Health Sciences of Walden University, MN, USA. Ukoh and John-Bull are grateful to friends in Uyo, Bauchi and Benin who motivated them on their studies.
CONTRIBUTION OF AUTHORS:
The idea in this work and the manuscript was developed by Ozurumba L.N.; Mr Ukoh V. was MSc Medical Parasitology student at Univ of Uyo Nigeria when this manuscript was developed while David J. is currently Msc Biology (Parasitology) student at ATBU Bauchi, Nigeria -these two other co-authors made their good contributions in the area of gathering other related literature information.
